Medicenna Therapeutics (TSE:MDNA) Shares Cross Below 200-Day Moving Average – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of C$1.79 and traded as low as C$0.93. Medicenna Therapeutics shares last traded at C$1.03, with a volume of 129,478 shares changing hands.

Medicenna Therapeutics Trading Up 9.6 %

The company has a 50 day moving average of C$1.34 and a 200 day moving average of C$1.79. The firm has a market cap of C$77.06 million, a P/E ratio of -2.84 and a beta of 1.21. The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40.

Insider Buying and Selling at Medicenna Therapeutics

In related news, Senior Officer David Hyman bought 20,000 shares of the business’s stock in a transaction on Thursday, January 9th. The shares were bought at an average cost of C$1.45 per share, for a total transaction of C$29,000.00. Corporate insiders own 22.57% of the company’s stock.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.